Name:	O
___	O
Unit	O
No:	O
___	O
Admission	O
Date:	O
___	O
Discharge	O
Date:	O
___	O
Date	O
of	O
Birth:	O
___	O
Sex:	O
M	O
Service:	O
MEDICINE	O
Allergies:	O
Corticosteroids	O
(Glucocorticoids)	O
/	O
Flagyl	O
Attending:	O
___	O
Chief	O
Complaint:	O
dysphagia,	O
nausea,	O
anorexia	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure:	O
Percutaneous	O
Bilateral	O
Nephrostomy	O
Tubes	O
___	O
Paracentesis	O
EGD	O
History	O
of	O
Present	O
Illness:	O
Primary	O
Oncologist:	O
___	O
Primary	O
Care	O
Physician:	O
___	O
.	O
HPI:	O
Mr.	O
___	O
is	O
a	O
___	O
yo	O
male	O
with	O
a	O
history	O
of	O
3	O
different	O
stage	O
III	O
melanoma	O
primaries,	O
now	O
with	O
metastatic	O
melanoma,	O
as	O
well	O
as	O
esophageal	O
Ca	O
(treated	O
with	O
chemo/	O
xrt)	O
diagnosed	O
in	O
___,	O
and	O
found	O
to	O
have	O
chest	O
wall	O
nodules	O
consistent	O
with	O
melanoma	O
in	O
___.	O
He	O
presents	O
to	O
clinic	O
with	O
dysphagia	O
and	O
anorexia.	O
He	O
presented	O
with	O
hyperbilirubinemia	O
in	O
___	O
and	O
was	O
found	O
to	O
have	O
common	O
bile	O
duct	O
dilation	O
with	O
a	O
distal	O
stomach	O
mass,	O
periportal	O
lymphadenopathy.	O
He	O
underwen	O
duodenal	O
stenting.	O
His	O
repeat	O
PET	O
showed	O
activity	O
in	O
the	O
liver.	O
This	O
stomach	O
mass	O
was	O
thought	O
to	O
be	O
most	O
likely	O
metastatic	O
melanoma	O
and	O
he	O
was	O
started	O
on	O
ipilimumab.	O
He	O
received	O
weeks	O
1,	O
4,	O
and	O
7	O
of	O
treatment.	O
He	O
was	O
due	O
for	O
week	O
10	O
the	O
day	O
before	O
admission	O
but	O
missed	O
treatment	O
secondary	O
to	O
nausea,	O
weight	B-Weight_loss
loss	B-Weight_loss
(10	O
lbs),	O
vomiting,	O
abdominal	O
distention.	O
.	O
He	O
states	O
that	O
for	O
the	O
past	O
2	O
weeks,	O
he	O
has	O
had	O
difficulty	O
swallowing	O
foods	O
but	O
also	O
some	O
liquids.	O
He	O
states	O
that	O
it	O
is	O
not	O
so	O
much	O
painful	O
as	O
it	O
is	O
difficult	O
to	O
physically	O
swallow.	O
He	O
has	O
been	O
forcing	O
himself	O
to	O
take	O
ensure	O
3x/day,	O
but	O
notes	O
that	O
when	O
he	O
forces	O
food,	O
he	O
sometimes	O
vomits	O
after.	O
He	O
notes	O
that	O
he	O
also	O
has	O
increased	O
acid	O
taste	O
in	O
his	O
mouth,	O
belching,	O
hiccuping,	O
and	O
bloating.	O
These	O
symptoms	O
of	O
reflux	O
cause	O
insomnia,	O
resulting	O
in	O
his	O
not	O
having	O
had	O
a	O
resftful	O
nights	O
sleep	O
in	O
2	O
weeks.	O
He	O
also	O
notes	O
increased	O
abdominal	O
distention.	O
He	O
was	O
seen	O
in	O
___	O
clinic	O
this	O
afternoon	O
and	O
he	O
was	O
found	O
to	O
have	O
abdominal	O
distention	O
and	O
right	O
sided	O
abdominal	O
fullness.	O
A	O
CT	O
abdomen	O
was	O
performed	O
and	O
showed	O
new	O
ascites.	O
He	O
was	O
referred	O
from	O
clinic	O
for	O
admission	O
for	O
evaluation	O
and	O
treatment	O
of	O
his	O
new	O
symptoms.	O
.	O
Review	O
of	O
Systems:	O
(+)	O
Per	O
HPI;	O
constipation	B-Constipation
for	O
the	O
past	O
6	O
days;	O
"fainting"	O
10	O
days	O
ago	O
in	O
a	O
store	O
after	O
hyperventillating;	O
no	O
presyncope	O
or	O
anxiety	O
since	O
that	O
time.	O
(-)	O
Denies	O
fever,	O
chills,	O
night	O
sweats.	O
Denies	O
blurry	O
vision,	O
diplopia,	O
loss	I-Visual_impairment
of	B-Visual_impairment
vision,	B-Visual_impairment
photophobia.	O
Denies	O
chest	O
pain	O
or	O
tightness,	O
palpitations.	O
Denies	O
cough,	O
shortness	O
of	O
breath,	O
or	O
wheezes.	O
Denies	O
melena,	B-Upper_gastrointestinal_haemorrhage
hematemesis,	B-Upper_gastrointestinal_haemorrhage
hematochezia.	B-Lower_gastrointestinal_haemorrhage
Denies	O
dysuria,	O
stool	B-Faecal_incontinence
or	O
urine	B-Urinary_incontinence
incontinence.	B-Faecal_incontinence
Denies	O
arthralgias	O
or	O
myalgias.	O
Denies	O
rashes	O
or	O
skin	O
breakdown.	O
All	O
other	O
systems	O
negative.	O
.	O
Past	O
Medical	O
History:	O
PAST	O
ONCOLOGIC	O
HISTORY:	O
--___	O
shave	O
biopsy	O
of	O
a	O
___	O
level	O
IV,	O
1	O
mm	O
thick,	O
nonulcerated	O
melanoma	O
from	O
his	O
left	O
flank	O
--___	O
wide	O
local	O
excision	O
with	O
sentinel	O
lymph	O
node	O
biopsy	O
in	O
with	O
pathology	O
revealing	O
residual	O
melanoma,	O
___	O
level	O
IV,	O
depth	O
0.5	O
mm	O
at	O
the	O
primary	O
site,	O
completely	O
excised.	O
--Wide	O
local	O
excision	O
with	O
sentinel	O
lymph	O
node	O
biopsy	O
___	O
showing	O
residual	O
melanoma,	O
5	O
left	O
axillary	O
and	O
1	O
sentinel	O
lymph	O
nodes	O
were	O
removed	O
--left	O
axillary	O
completion	O
node	O
dissection	O
___	O
with	O
pathology	O
showing	O
no	O
residual	O
melanoma	O
in	O
21	O
nodes	O
--adjuvant	O
IFN	O
therapy	O
___	O
--new	O
primary	O
melanoma	O
left	O
nasal	O
skin	O
___	O
s/p	O
wide	O
local	O
excision	O
with	O
sentinel	O
lymph	O
node	O
biopsy	O
+	O
--left	O
neck	O
node	O
dissection	O
___	O
with	O
no	O
residual	O
melanoma	O
present	O
--local	O
recurrence	O
in	O
the	O
left	O
flank	O
scar	O
___	O
s/p	O
wide	O
excision	O
with	O
clear	O
margins	O
.	O
Esophageal	O
cancer:	O
--___	O
progressive	O
reflux	O
symptoms,	O
EGD	O
showed	O
partially	O
obstructing	O
esophageal	O
mass	O
with	O
bx	O
positive	O
for	O
poorly	O
differentiated	O
adenocarcinoma,	O
signet	O
ring	O
cell	O
type	O
--PET	O
___	O
mild	O
FDG	O
uptake	O
GE	O
juct,	O
FDG-avid	O
lymphadenopathy	O
along	O
the	O
celiac	O
axis;	O
FDG	O
uptake	O
in	O
left	O
chest	O
wall	O
subcutaneous	O
nodules;	O
and	O
lung	O
nodules	O
consistent	O
with	O
multifocal	O
pneumonia	B-Lower_respiratory_tract_infection
--underwent	O
6	O
weeks	O
of	O
chemoradiation	O
with	O
Drs.	O
___	O
___	O
at	O
___,	O
completing	O
therapy	O
in	O
early	O
___	O
per	O
___	O
records,	O
patient	O
says	O
___	O
--scheduled	O
for	O
repeat	O
EGD	O
in	O
___	O
.	O
Distal	O
Stomach	O
Mass:	O
(likely	O
metastatic	O
melanoma)	O
-___	O
he	O
presented	O
with	O
hyperbilirubinemia	O
without	O
symptoms.	O
US	O
done	O
locally	O
showed	O
CBD	O
dilatation.	O
-	O
___	O
presented	O
to	O
___	O
with	O
hematemesis	B-Upper_gastrointestinal_haemorrhage
and	O
was	O
transferred	O
here	O
-EGD	O
without	O
recurrent	O
esophageal	O
mass,	O
but	O
distal	O
stomach	O
mass	O
noted.	O
-Abd	O
CT	O
showed	O
a	O
large	O
soft	O
tissue	O
density	O
involving	O
the	O
distal	O
stomach,	O
the	O
duodenum	O
and	O
the	O
distal	O
portion	O
of	O
the	O
common	O
bile	O
duct	O
causing	O
obstruction;	O
pathology	O
of	O
gastric	O
and	O
duodenal	O
biopsies	O
did	O
not	O
demonstrate	O
malignancy.	O
He	O
underwent	O
ERCP	O
and	O
placement	O
of	O
duodenal	O
stent	O
and	O
percutaneous	O
bile	O
duct	O
drainage/stent.	O
He	O
has	O
undergone	O
repeat	O
cytology	O
of	O
CBD	O
brushings	O
and	O
biopsy	O
of	O
peripancreatic	O
LN's	O
with	O
no	O
malignancy	O
identified.	O
He	O
underwent	O
PET	O
CT	O
on	O
___	O
with	O
FDG	O
avidity	O
in	O
new	O
liver	O
lesions	O
and	O
celiac	O
and	O
internal	O
mammary	O
lymph	O
nodes,	O
felt	O
most	O
consistent	O
with	O
metastatic	O
melanoma.	O
He	O
started	O
ipilimumab	O
off	O
protocol	O
on	O
___.	O
-	O
Underwent	O
week	O
1,	O
4,	O
and	O
7	O
week	O
of	O
ipilimumab	O
and	O
then	O
missed	O
week	O
10	O
due	O
to	O
nausea,	O
vomiting,	O
weight	B-Weight_loss
loss.	B-Weight_loss
.	O
Prostate	O
cancer:	O
--s/p	O
brachytherapy	O
___	O
.	O
Social	O
History:	O
___	O
Family	O
History:	O
Father	O
deceased	O
from	O
prostate	O
cancer	O
in	O
his	O
___.	O
Mother	O
deceased	O
from	O
CVA	O
in	O
her	O
___.	O
Physical	O
Exam:	O
PHYSICAL	O
EXAM:	O
Vitals	O
T97.7	O
bp	O
153/86	O
HR	O
103	O
RR	O
17	O
SaO2	O
100RA	O
GENERAL:	O
NAD	O
HEENT:	O
AT/NC,	O
EOMI,	O
anicteric	O
sclera,	O
pink	O
conjunctiva,	O
dry	O
mucous	O
membranes	O
CARDIAC:	O
RRR,	O
S1/S2,	O
no	O
murmers,	O
gallops,	O
or	O
rubs	O
LUNG:	O
CTAB,	O
no	O
wheezes,	O
rales,	O
rhonchi,	O
breathing	O
comfortably	O
without	O
use	O
of	O
accessory	O
muscles	O
ABDOMEN:	O
distended,	O
tympanic	O
without	O
rebound	O
or	O
guarding,	O
nontender	O
in	O
all	O
quadrants,	O
no	O
masses	O
EXTREMITIES:	O
moving	O
all	O
extremities	O
well,	O
no	O
cyanosis,	O
clubbing	O
NEURO:	O
no	O
focal	O
deficits	O
SKIN:	O
warm	O
and	O
well	O
perfused,	O
no	O
excoriations	O
or	O
lesions,	O
no	O
rashes	O
PSYCH:	O
cooperative	O
.	O
Pertinent	O
Results:	O
___	O
03:20PM	O
UREA	O
N-33*	O
CREAT-1.3*	O
SODIUM-139	O
POTASSIUM-3.9	O
CHLORIDE-99	O
TOTAL	O
CO2-32	O
ANION	O
GAP-12	O
___	O
03:20PM	O
ALT(SGPT)-21	O
AST(SGOT)-30	O
LD(LDH)-234	O
ALK	O
PHOS-92	O
TOT	O
BILI-1.0	O
___	O
03:20PM	O
ALBUMIN-3.8	O
___	O
03:20PM	O
TSH-2.1	O
___	O
03:20PM	O
WBC-10.0	O
RBC-4.28*	O
HGB-13.5*	O
HCT-38.5*	O
MCV-90	O
MCH-31.5	O
MCHC-35.0	O
RDW-12.9	O
___	O
03:20PM	O
PLT	O
COUNT-199	O
.	O
EGD	O
___:	O
Moderate	O
esophagitis	O
noted	O
in	O
the	O
lower	O
third	O
of	O
the	O
esophagus.	O
A	O
cold	O
forceps	O
biopsy	O
was	O
performed	O
for	O
histology.	O
The	O
duodenal	O
stent	O
was	O
seen	O
well	O
positioned	O
and	O
was	O
patent.	O
A	O
biliary	O
stent	O
was	O
seen	O
at	O
the	O
papila.	O
CYTOLOGY	O
OF	O
PERITONEAL	O
FLUID	O
___:	O
POSITIVE	O
FOR	O
MALIGNANT	O
CELLS,	O
consistent	O
with	O
poorly	O
differentiated	O
adenocarcinoma.	O
PATHOLOGY:	O
___	O
Esophagus	O
biopsy:	O
Squamous	O
epithelium	O
with	O
focal	O
active	O
esophagitis.	O
___	O
A.	O
FNA,	O
Gastric	O
wall,	O
cell	O
block	O
:	O
Negative	O
for	O
Malignant	O
Cells.	O
Consistent	O
with	O
mucosal	O
gastric	O
sampling.	O
.	O
B.	O
FNA	O
Celiac	O
lymph	O
node	O
with	O
and	O
without	O
suction,	O
cell	O
block:	O
Atypical.	O
.	O
Scattered	O
atypical	O
cells	O
in	O
a	O
mucinous	O
background	O
of	O
undetermined	O
significance.	O
.	O
IMAGING:	O
CT	O
Head	O
___	O
IMPRESSION:	O
1.	O
No	O
enhancing	O
brain	O
lesions	O
are	O
seen.	O
2.	O
No	O
lytic	O
or	O
sclerotic	O
lesions	O
are	O
identified	O
in	O
the	O
bony	O
structures.	O
3.	O
There	O
is	O
mild	O
mucosal	O
thickening	O
in	O
the	O
partially	O
visualized	O
right	O
maxillary	O
sinus.	O
4.	O
Mild-to-moderate	O
ventriculomegaly,	O
out	O
of	O
proportion	O
for	O
sulci,	O
unchanged	O
from	O
prior	O
CT	O
of	O
___.	O
.	O
PET	O
___	O
IMPRESSION:	O
1.	O
New	O
FDG-avid	O
left	O
internal	O
mammary	O
lymph	O
node	O
with	O
decrease	O
in	O
the	O
size	O
and	O
FDG	O
avidity	O
of	O
one	O
chest	O
wall	O
nodule.	O
Other	O
previously	O
noted	O
left	O
internal	O
mammary	O
and	O
chest	O
wall	O
nodules	O
show	O
little	O
chance.	O
2.	O
New	O
enlarged	O
and	O
FDG	O
avid	O
celiac	O
axis	O
lymph	O
node	O
is	O
most	O
likely	O
related	O
to	O
patients	O
duodenal/gastric	O
malignancy.	O
3.	O
New	O
FDG	O
avid	O
lesions	O
in	O
segment	O
VI	O
and	O
VII	O
of	O
the	O
liver	O
could	O
be	O
related	O
to	O
melanoma	O
or	O
GI	O
malignancy.	O
4.	O
Mild	O
increased	O
uptake	O
in	O
the	O
esophagus	O
close	O
to	O
the	O
GE	O
junction	O
could	O
be	O
related	O
to	O
inflammation	O
secondary	O
to	O
reflux	O
or	O
residual/	O
recurrent	O
disease.	O
.	O
___	O
07:23AM	O
BLOOD	O
WBC-8.7	O
RBC-3.43*	O
Hgb-10.6*	O
Hct-30.8*	O
MCV-90	O
MCH-30.8	O
MCHC-34.4	O
RDW-13.7	O
Plt	O
___	O
___	O
04:26PM	O
BLOOD	O
WBC-8.1	O
RBC-3.65*	O
Hgb-11.5*	O
Hct-32.9*	O
MCV-90	O
MCH-31.6	O
MCHC-35.0	O
RDW-13.0	O
Plt	O
___	O
___	O
04:30AM	O
BLOOD	O
WBC-13.2*#	O
RBC-3.13*	O
Hgb-9.8*	O
Hct-28.0*	O
MCV-90	O
MCH-31.5	O
MCHC-35.2*	O
RDW-13.1	O
Plt	O
___	O
___	O
07:15PM	O
BLOOD	O
WBC-11.9*	O
RBC-3.20*	O
Hgb-9.8*	O
Hct-29.1*	O
MCV-91	O
MCH-30.7	O
MCHC-33.7	O
RDW-13.9	O
Plt	O
___	O
___	O
09:50AM	O
BLOOD	O
WBC-10.5	O
RBC-3.29*	O
Hgb-10.5*	O
Hct-29.8*	O
MCV-91	O
MCH-31.9	O
MCHC-35.2*	O
RDW-14.0	O
Plt	O
___	O
___	O
04:00AM	O
BLOOD	O
WBC-7.9	O
RBC-2.87*	O
Hgb-9.1*	O
Hct-25.8*	O
MCV-90	O
MCH-31.6	O
MCHC-35.1*	O
RDW-13.0	O
Plt	O
Ct-96*	O
___	O
04:30AM	O
BLOOD	O
WBC-7.7	O
RBC-2.81*	O
Hgb-8.9*	O
Hct-25.1*	O
MCV-89	O
MCH-31.5	O
MCHC-35.3*	O
RDW-13.1	O
Plt	O
___	O
___	O
06:00AM	O
BLOOD	O
WBC-7.5	O
RBC-2.77*	O
Hgb-8.8*	O
Hct-24.4*	O
MCV-88	O
MCH-31.8	O
MCHC-36.1*	O
RDW-12.9	O
Plt	O
___	O
Brief	O
Hospital	O
Course:	O
Patient	O
is	O
an	O
___	O
yo	O
male	O
with	O
metastatic	O
melanoma,	O
esophageal	O
cancer,	O
distal	O
stomach	O
mass	O
of	O
unknown	O
primary	O
but	O
thought	O
to	O
be	O
metastatic	O
melanoma	O
who	O
presented	O
after	O
3	O
cycles	O
of	O
ipilimumab	O
(on	O
week	O
10	O
of	O
ipilimumab	O
treatment)	O
with	O
nausea,	O
vomiting,	O
dysphagia,	O
abdominal	O
distention	O
and	O
new	O
ascites.	O
.	O
#Dysphagia,	O
Nausea,	O
Vomiting	O
-	O
patient	O
has	O
a	O
history	O
of	O
radiation	O
esphagitis	O
and	O
may	O
have	O
developed	O
a	O
subsequent	O
stricture.	O
Also	O
on	O
differential	O
was	O
his	O
abdominal	O
mass	O
causing	O
obstruction.	O
Therefore	O
was	O
GI	O
consulted	O
and	O
pt	O
underwent	O
EGD	O
which	O
showed	O
moderate	O
esophagitis	O
noted	O
in	O
the	O
lower	O
third	O
of	O
the	O
esophagus,	O
patent	O
duodenal	O
stent	O
and	O
biliary	O
stent	O
was	O
seen	O
at	O
the	O
papila.	O
Pt	O
continued	O
to	O
have	O
reflux	O
symptoms	O
spit	O
up	O
coffee	O
ground	O
emesis	O
several	O
times	O
during	O
hospitalization.	O
Pt's	O
PPI	O
was	O
increased	O
and	O
pt	O
received	O
Simethacone	O
PRN.	O
Pt	O
was	O
also	O
put	O
on	O
soft,	O
pureed	O
diet.	O
.	O
#	O
Metastatic	O
melanoma	O
-	O
s/p	O
3	O
cycles	O
of	O
ipilimumab.	O
Although	O
pt	O
found	O
not	O
to	O
have	O
much	O
benefit	O
from	O
chemo	O
treatment	O
thus	O
far.	O
TSH	O
was	O
within	O
normal	O
limits	O
for	O
screening	O
for	O
hypophysitis.	O
Family	O
meeting	O
took	O
place	O
with	O
pt,	O
son,	O
and	O
ex-wife	O
___onfirmed	O
desire	O
to	O
be	O
DNR/DNI	O
and	O
to	O
be	O
bridged	O
to	O
a	O
___	O
facility.	O
Pt	O
expressed	O
desires	O
to	O
be	O
treated	O
for	O
infection	O
while	O
here	O
but	O
not	O
to	O
have	O
any	O
more	O
invasive	O
procedures	O
(eg	O
lower	O
endoscopy).	O
Pallative	O
care	O
consulted	O
and	O
case	O
management	O
made	O
aware	O
of	O
pt's	O
desires.	O
.	O
#Sepsis:	O
Patient	O
with	O
GNR,	O
Klebsiella	O
pneumoniae,	O
transient	O
bacteremia.	O
Likely	O
related	O
to	O
perc	O
nephrostomy	O
tube	O
placement.	O
Patient	O
now	O
afebrile	O
with	O
no	O
leukocytosis	O
and	O
tachycardia	O
resolved.	O
Shortly	O
after	O
nephrostomy	O
tubes	O
placed,	O
pt	O
developed	O
a	O
fever,	O
tachycardia,	O
rigors,	O
and	O
acute	O
leukocytosis.	O
Blood	O
cultures	O
were	O
sent	O
which	O
came	O
back	O
positive	O
for	O
GNRs,	O
Klebsiella	O
pneumoniae.	O
Cefepime	O
initially	O
started	O
and	O
switched	O
to	O
Ceftriaxone	O
as	O
speciation	O
was	O
known.	O
Pt	O
will	O
require	O
continuation	O
of	O
antibiotics	O
until	O
___.	O
#Ascites	O
-	O
pt	O
found	O
to	O
be	O
more	O
distended	O
than	O
usual.	O
There	O
was	O
no	O
evidence	O
of	O
SBP	O
and	O
pt	O
underwent	O
___	O
paracentesis.	O
SAAG	O
was	O
.2	O
and	O
polys	O
were	O
<<200	O
indicating	O
unlikley	O
portal	O
HTN	O
and	O
unlikely	O
SBP.	O
Cytology	O
for	O
peritoneal	O
fluid	O
was	O
POSITIVE	O
FOR	O
MALIGNANT	O
CELLS,	O
consistent	O
with	O
poorly	O
differentiated	O
adenocarcinoma.	O
.	O
#Nausea/Vomiting	O
-	O
pt	O
received	O
Zofran,	O
Compazine	O
PRN	O
.	O
#PPx	O
-	O
venodynes	O
Transitional	O
Issues:	O
======================	O
-Pt	O
to	O
receive	O
Ceftriaxone	O
until	O
___	O
for	O
transient	O
bacteremia	O
-Pt	O
remained	O
DNR/DNI	O
while	O
hospitalized	O
-Transition	O
to	O
hospice	O
after	O
acute	O
rehab	O
Medications	O
on	O
Admission:	O
Preadmission	O
medications	O
listed	O
are	O
correct	O
and	O
complete.	O
Information	O
was	O
obtained	O
from	O
PatientwebOMR.	O
1.	O
Latanoprost	O
0.005%	O
Ophth.	O
Soln.	O
1	O
DROP	O
BOTH	O
EYES	O
HS	O
ON	O
ODD-NUMBERED	O
DAYS	O
2.	O
Lorazepam	O
0.5	O
mg	O
PO	O
BID:PRN	O
anxiety	O
3.	O
MetronidAZOLE	O
Topical	O
1	O
%	O
Gel	O
1	O
Appl	O
TP	O
BID:PRN	O
rash	O
4.	O
Omeprazole	O
20	O
mg	O
PO	O
DAILY	O
.	O
Discharge	O
Medications:	O
1.	O
Latanoprost	O
0.005%	O
Ophth.	O
Soln.	O
1	O
DROP	O
BOTH	O
EYES	O
HS	O
ON	O
ODD-NUMBERED	O
DAYS	O
2.	O
MetronidAZOLE	O
Topical	O
1	O
%	O
Gel	O
1	O
Appl	O
TP	O
BID:PRN	O
rash	O
3.	O
Omeprazole	O
40	O
mg	O
PO	O
BID	O
4.	O
Bisacodyl	O
___ID:PRN	O
constipation	B-Constipation
5.	O
CeftriaXONE	O
2	O
gm	O
IV	O
Q24H	O
6.	O
Docusate	O
Sodium	O
100	O
mg	O
PO	O
BID:PRN	O
constipation	B-Constipation
7.	O
Loperamide	O
2	O
mg	O
PO	O
QID:PRN	O
diarrhea	O
8.	O
OxycoDONE	O
(Immediate	O
Release)	O
5	O
mg	O
PO	O
Q4H:PRN	O
pain	O
did	O
not	O
give	O
if	O
oversedated	O
or	O
rr<10	O
9.	O
Polyethylene	O
Glycol	O
17	O
g	O
PO	O
DAILY:PRN	O
constipation	B-Constipation
1st	O
dose	O
now	O
please	O
10.	O
Prochlorperazine	O
10	O
mg	O
PO	O
Q6H:PRN	O
nausea	O
11.	O
Senna	O
1	O
TAB	O
PO	O
BID:PRN	O
constipation	B-Constipation
12.	O
Simethicone	O
40-80	O
mg	O
PO	O
QID:PRN	O
bloating	O
13.	O
Acetaminophen	O
325-650	O
mg	O
PO	O
Q6H:PRN	O
Pain	O
14.	O
Aluminum-Magnesium	O
Hydrox.-Simethicone	O
___	O
mL	O
PO	O
QID:PRN	O
Reflux	O
15.	O
Haloperidol	O
___	O
mg	O
PO	O
Q8H:PRN	O
Hiccups	O
16.	O
traZODONE	O
25	O
mg	O
PO	O
HS:PRN	O
insomnia	O
Discharge	O
Disposition:	O
Extended	O
Care	O
Facility:	O
___	O
Discharge	O
Diagnosis:	O
Metastatic	O
Melanoma	O
Esophagitis	O
Esophageal	O
Cancer	O
Bacteremia	O
Acute	O
Kidney	O
Injury	O
Discharge	O
Condition:	O
Mental	B-Delirium
Status:	B-Delirium
Clear	B-Delirium
and	B-Delirium
coherent.	B-Delirium
Level	O
of	O
Consciousness:	O
Alert	O
and	O
interactive.	O
Activity	O
Status:	O
Ambulatory	B-Mobile_with_assistance
-	B-Mobile_with_assistance
requires	B-Mobile_with_assistance
assistance	B-Mobile_with_assistance
or	O
aid	B-Mobile_with_aid
(walker	O
or	O
cane).	O
Discharge	O
Instructions:	O
Mr.	O
___,	O
It	O
was	O
pleasure	O
taking	O
care	O
of	O
you	O
here	O
at	O
___.	O
You	O
were	O
admitted	O
because	O
of	O
increased	O
difficulty	O
in	O
swallowing,	O
nausea,	O
and	O
vomiting.	O
You	O
had	O
several	O
tests	O
to	O
evaluate	O
if	O
there	O
was	O
a	O
blockage	O
in	O
you	O
esophagus,	O
stomach,	O
or	O
small	O
intestine.	O
These	O
tests	O
indicated	O
that	O
you	O
did	O
not	O
have	O
a	O
blockage	O
and	O
revealed	O
that	O
you	O
have	O
severe	O
esophagitis.	O
While	O
hospitalized	O
it	O
was	O
discovered	O
that	O
your	O
kidneys	O
were	O
not	O
working	O
properly,	O
likely	O
due	O
to	O
a	O
blockage	O
in	O
the	O
bladder	O
and/or	O
ureters.	O
You	O
received	O
two	O
nephrostomy	O
tubes	O
to	O
help	O
relieve	O
the	O
pressure	O
within	O
the	O
kidneys	O
and	O
your	O
kidney	O
function	O
returned	O
to	O
normal.	O
Shortly	O
after	O
having	O
these	O
tubes	O
placed,	O
you	O
developed	O
a	O
fever	O
and	O
it	O
was	O
discovered	O
that	O
bacteria	O
was	O
in	O
your	O
blood	O
therefore	O
you	O
were	O
started	O
on	O
antibiotics	O
which	O
you	O
should	O
continue	O
once	O
discharged.	O
You	O
expressed	O
your	O
desires	O
to	O
the	O
medical	O
team	O
while	O
here	O
that	O
you	O
would	O
like	O
to	O
be	O
transitioned	O
to	O
a	O
rehab	O
facility	O
and	O
then	O
to	O
hospice.	O
Followup	O
Instructions:	O
___	O

